Free Trial

biote (NASDAQ:BTMD) Downgraded by B. Riley to Neutral

biote logo with Medical background

Key Points

  • B. Riley has downgraded biote (NASDAQ:BTMD) from a "buy" rating to a "neutral" rating, with a revised price target of $4.00 down from $8.00.
  • During trading on Thursday, biote's stock fell 24.4%, closing at $2.92, amidst significant trading volume of 826,213 shares.
  • Institutional investors have significantly increased their positions in biote, with CWM LLC notably raising its holdings by 952.7% in the last quarter.
  • Need better tools to track biote? Try 5 Weeks of MarketBeat All Access for $5. Start Portfolio Tracking Now.

B. Riley downgraded shares of biote (NASDAQ:BTMD - Free Report) from a buy rating to a neutral rating in a research note published on Thursday morning, Marketbeat reports. B. Riley currently has $4.00 price objective on the stock, down from their prior price objective of $8.00. B. Riley also issued estimates for biote's Q3 2025 earnings at $0.03 EPS.

biote Stock Performance

biote stock traded up $0.02 during trading on Thursday, reaching $2.90. 291,513 shares of the company's stock were exchanged, compared to its average volume of 169,490. The company's 50-day moving average is $4.00 and its two-hundred day moving average is $4.01. biote has a 52-week low of $2.76 and a 52-week high of $6.98. The firm has a market cap of $158.66 million, a price-to-earnings ratio of 3.23 and a beta of 1.21.

biote (NASDAQ:BTMD - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.10 EPS for the quarter, topping analysts' consensus estimates of $0.06 by $0.04. biote had a net margin of 15.73% and a negative return on equity of 19.71%. The firm had revenue of $48.86 million for the quarter, compared to analyst estimates of $49.52 million. Analysts anticipate that biote will post 0.75 EPS for the current year.

Institutional Investors Weigh In On biote

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BTMD. Acadian Asset Management LLC increased its holdings in shares of biote by 15.0% during the 1st quarter. Acadian Asset Management LLC now owns 700,871 shares of the company's stock worth $2,330,000 after purchasing an additional 91,672 shares during the period. Dimensional Fund Advisors LP grew its position in shares of biote by 0.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 681,524 shares of the company's stock worth $4,211,000 after buying an additional 3,065 shares during the period. Geode Capital Management LLC grew its holdings in biote by 7.2% during the second quarter. Geode Capital Management LLC now owns 616,697 shares of the company's stock valued at $2,480,000 after purchasing an additional 41,333 shares during the period. Northern Trust Corp raised its position in biote by 9.9% during the fourth quarter. Northern Trust Corp now owns 288,336 shares of the company's stock worth $1,782,000 after acquiring an additional 25,873 shares in the last quarter. Finally, Nuveen LLC bought a new stake in biote during the first quarter worth $872,000. Hedge funds and other institutional investors own 21.68% of the company's stock.

About biote

(Get Free Report)

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.

Featured Stories

Should You Invest $1,000 in biote Right Now?

Before you consider biote, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and biote wasn't on the list.

While biote currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings: All Signs Point to More Growth Ahead
3 Quiet Growth Stocks With Major Momentum
The Market’s Next Big Winners? Start Here

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines